Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Turkmenistan Health News.
Press releases published on October 13, 2025
Pharmacist Moms Group® Honors 2025 Women Pharmacist of the Year Award Winners
The annual awards program recognizes women pharmacists whose leadership and innovation have advanced health care and made an impact in communities nationwide. MONROE, N.J., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Pharmacist Moms Group® (PhMG) has announced the …
New Study Confirms Stress-Reduction Benefits of Natural Remedies’ Ashwa.30
BANGALORE, India, Oct. 13, 2025 (GLOBE NEWSWIRE) -- A new study conducted by Clinical Research Australia reinforces the stress-reducing potential of Natural Remedies’ Ashwa.30, a next-generation ashwagandha extract. The results will be presented at …
General Oncology to Present Preliminary Phase 1 Results from SHARON Trial in Patients with BRCA/PALB2-mutated Pancreatic and Breast Cancer at ESMO 2025
BOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- General Oncology, Inc. (“General Oncology” or the “Company”), a clinical-stage biopharmaceutical company dedicated to pioneering first-in-class medicines for metastatic cancers, today announced that it will deliver …
Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that complete data from the Phase 2b trial of rosnilimab, a …
PacBio HiFi Technology Selected as Core Platform for South Korea’s National Pangenome Project
MENLO PARK, Calif. and SEOUL, South Korea, Oct. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that its HiFi sequencing technology has been selected as the …
Humanitarian Nonprofit Human Appeal USA to Host National Comedy Tour
MISSION VIEJO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Humanitarian aid nonprofit, Human Appeal USA, is kicking off their national comedy takeover tour featuring famous comedians to raise money in support of Human Appeal’s emergency appeals to deliver …
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108
PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD) and ulcerative colitis (UC) to address significant unmet medical needs Carlsbad, CA, Oct. 13, 2025 (GLOBE NEWSWIRE) -- …
Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements
HOUSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on October 10, 2025 the Company received notice from the Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with …
Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today …
Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer’s and Traumatic Brain Injury Programs
HOUSTON, TX, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the appointment of Dr. Robert Rothstein, …
Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today …
Auron Therapeutics to Participate in the 8th Annual Targeted Protein Degradation & Induced Proximity Summit
NEWTON, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced that members of its leadership …
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes
If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapy sBLA submission based on data from the Phase 3 INHALE-1 study PDUFA target action date of May 29, 2026 WESTLAKE VILLAGE, Calif. and …
Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025
Presentation will cover two-year clinical efficacy, immunogenicity and safety data Data will be presented at an oral session on October 17, 2025, followed by a webinar on October 22, 2025, providing further insights into the clinical findings COPENHAGEN, …
SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025
NEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, …
Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing
STOUGHTON, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management team will ring the Nasdaq opening bell on October 14, 2025 at 9:30 a.m. ET in celebration of its 10-year anniversary as a …
Hinge Bio Announces FDA Clearance of Investigational New Drug Application for HB2198, a Novel B cell-Depleting Agent, for Patients with Systemic Lupus Erythematosus and Lupus Nephritis
BURLINGAME, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Hinge Bio, Inc., a privately-held biotechnology company engaged in the discovery and development of innovative multi-specific medicines, announced the U.S. Food and Drug Administration (“FDA”) has …
HMNC Brain Health Presents New Analysis Supporting Rationale for Combining a Genetic Patient Selection Tool with a Vasopressin V1b Receptor Antagonist in the Treatment of Depression at ISCTM Conference in Amsterdam
MUNICH, Oct. 13, 2025 (GLOBE NEWSWIRE) -- HMNC Brain Health, a clinical-stage precision psychiatry biopharmaceutical company developing personalized treatments powered by predictive companion diagnostics, today announced it presented a retrospective …
Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will be presenting late- …